Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Nakamichi K, Shen JZ, Lee CS, Lee AY, Roberts EA, Simonson PD, et al. Outcomes associated with SARS-CoV-2 viral clades in COVID-19. medRxiv. 2020.

Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156-2168.

Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin Cancer Res. 2020;26(7):1624-1632.

Kim J-, Lin C, Stavre Z, Greenblatt MB, Shim J-. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020;9(9).

Satlin MJ, Goyal P, Magleby R, Maldarelli GA, Pham K, Kondo M, et al. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS One. 2020;15(7):e0236778.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020;182(2):297-316.e27.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, et al. Loss with Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2020;203(2):344-350.

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? Haematologica. 2020;105(6):e276-e279.

Bok S, Shin DY, Yallowitz AR, Eiseman M, Cung M, Xu R, et al. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nat Commun. 2020;11(1):5704.

Armache A, Yang S, de Paz AM, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature. 2020;583(7818):852-857.